developing psychedelics into prescription medicines: mdma-assisted psychotherapy for posttraumatic...
TRANSCRIPT
![Page 1: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/1.jpg)
Developing Psychedelics into Prescription Medicines:
MDMA-Assisted Psychotherapy for Posttraumatic Stress
DisorderBy Rick Doblin, PhD, Executive Director
Multidisciplinary Association for Psychedelic Studies
Entheogenesis Australias December 4, 2010
![Page 2: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/2.jpg)
Replacing Fears... With Facts
![Page 3: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/3.jpg)
•“Probably the worst example they could find of a drug lab they had raided and taken a photo of.” -Dr. David E. Nichols, Ph.D.
•“I love the way the way they always throw the battery acid and drain cleaner into the story, as if prescription drugs were not manufactured using the exact same reagents, which are simply dilute sulfuric acid and sodium hydroxide!” -Dr. Nicholas Vito Cozzi, Ph.D.
![Page 4: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/4.jpg)
Brain SPECT Scan-MTV/Oprah
Holes in the Brain from MDMA?
(Ecstasy. Create Fear.)
![Page 5: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/5.jpg)
![Page 6: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/6.jpg)
![Page 7: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/7.jpg)
![Page 8: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/8.jpg)
Leshner Testimony to Senate Leshner Testimony to Senate Subcommittee on Government Subcommittee on Government
Affairs 7/30/01Affairs 7/30/01
![Page 9: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/9.jpg)
![Page 10: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/10.jpg)
![Page 11: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/11.jpg)
Bottle from experiement of MDMA
Harvard MDMA Cancer - ask John
![Page 12: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/12.jpg)
![Page 13: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/13.jpg)
![Page 14: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/14.jpg)
Documentary Clip
![Page 15: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/15.jpg)
Outline •Why MDMA?
•Why PTSD?
•Questions for Phase II trials
•US Pilot study & follow-up: Design & Results
• International series of Phase II studies
•US MDMA/PTSD war veterans study
•Australian MDMA/PTSD study?
![Page 16: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/16.jpg)
Why MDMA?•Reduces fear response to perceived
emotional threat (reduced activity in amygdala; Gamma, A., et al., 2002)
• Increases trust and empathy (oxytocin, prolactin, similar to post-orgasmic state; Passie et al., 2005)
•Gentle but profound; easier to integrate
•Therapists/psychiatrists more willing to self-experiment than classic psychedelics
![Page 17: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/17.jpg)
Why MDMA?
•Highly demonized: 3500+ papers in Medline about risks/mechanisms of action
•Estimated cost $300 million worth of studies in the public domain
•MAPS spent $150,000 to read and summarize all published scientific peer-reviewed literature on MDMA
![Page 18: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/18.jpg)
Why PTSD? •Current treatment approaches fail to provide relief in a substantial number of patients
• Internationally accepted outcome measure (CAPS)
•Therapeutic change captured by outcome measure (not the case with psychedelic therapy for end-of-life anxiety & depression)
•Highly sympathetic patient population (Veterans, survivors of sexual assault, abuse, accidents, and trauma)
![Page 19: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/19.jpg)
Why PTSD? PTSD
A fear-based disorderMDMA
Treatment for fear
$300 million of existing research
Millions of users, rare side effects known
Top priority combination of psychedelic drug and clinical
condition
=
![Page 20: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/20.jpg)
Phase II Methodological
Issues •Development of our therapeutic model
•Training of therapists
•Cause of PTSD related to treatment method?
•Successful double-blind design
•Variance and magnitude of treatment effect
•Cultural differences
![Page 22: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/22.jpg)
Training Therapists •5 day training program mostly watching
videos and reviewing treatment manual and adherence criteria
•Psychological effects of MDMA administration in normal volunteers training to conduct MDMA-assisted psychotherapy research
•Review video tapes of first two therapy sessions by raters scoring adherence criteria with feedback from Mithoefers
![Page 23: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/23.jpg)
Cause of PTSD Related to
Treatment Method?•Sexual assault vs. war-related
trauma?
![Page 24: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/24.jpg)
Successful Double-Blinding
•Inactive placebo
•Active placebo
•Dose response
![Page 25: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/25.jpg)
Treatment Effect (Variance & Magnitude)
•Data from US versus Swiss
•get Swiss data from Ilsa
![Page 26: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/26.jpg)
Cultural Differences
![Page 27: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/27.jpg)
US MDMA/PTSD Pilot Study Design•Treatment resistant/pharmacotherapy
& psychotherapy
•Average duration PTSD = 19 years
• Inactive placebo versus 125mg + 62.5mg
•Combination: drug & non-drug psychotherapy
•2-3 MDMA sessions with 2 month & long-term follow-up
![Page 28: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/28.jpg)
Treatment Process
• In addition, therapists have up to a 30-minute phone session with participant for 7 days following each experimental session.
• Outcome Assesment = 2 months after last experimental session
• Follow-up Assessment = 12 months after last experimental session
ScreeninScreening/g/
BaselineBaseline
90-Minute Non-Drug 90-Minute Non-Drug Intro Therapy SessionsIntro Therapy Sessions
11 22 33
MDMA or Placebo
11
22
33
90- Min Non-Drug Integrative
Therapy Sessions
Exp Exp SessionSession
11
22
33Exp Exp
SessionSessionExp Exp
SessionSession
11
22
33
MDMA or Placebo
MDMA or Placebo
Non-Drug IntegrativeTherapy Sessions
Non-Drug IntegrativeTherapy Sessions
OOuuttccoommee
FFoollllooww
UUpp
![Page 29: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/29.jpg)
![Page 30: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/30.jpg)
![Page 31: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/31.jpg)
get from ilsa orMM this yellow colum should be 25%
![Page 32: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/32.jpg)
![Page 33: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/33.jpg)
![Page 34: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/34.jpg)
US Long-Term Follow-Up
![Page 35: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/35.jpg)
Swiss MDMA/PTSD• Improvements not observed in active
placebo group 25mg + 12.5mg BUT did produce some blinding
• MDMA group benefited, but not as much as in US MDMA/PTSD study
• No Serious Adverse Events (no evidence of harm)
• Long-term follow-up to be completed Jan 2011; paper submitted to journal by April 2011
![Page 36: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/36.jpg)
•graph of Swiss data
![Page 37: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/37.jpg)
Swiss •Physiological correlates of PTSD
study conducted by Dr Franz X. Vollenweider, M.D. @ University of Zurich in all 12 participants
•EEG
•Startle reflex
•Heart rate variability (HRV)
•Results will be published as a separate paper
![Page 38: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/38.jpg)
Israel
•5 patients
• No Serious Adverse Events (no evidence of harm)
•No efficacy
![Page 39: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/39.jpg)
Current & Upcoming
Studies
•Canada
•Israel
•Jordan
•US MDMA/PTSD War Veterans
![Page 40: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/40.jpg)
Canada•Can we replicate US results in a
similar cultural context with similarly trained therapists?
•N = 12
•125mg + 62.5mg versus 25mg + 12.5mg
•3 sessions
•Waiting on import permit
![Page 41: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/41.jpg)
Israel
•Different cultural context
•2 sessions instead of 3
•N = 10
•125 + 62.5 versus 25 + 12.5
•Traditional psychiatrists paired with psychologists experienced with PTSD or MDMA
![Page 42: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/42.jpg)
Jordan •Different cultural context
•How do we teach our method?
•N = 12 Iraqi refugees in Jordan
•3 Sessions
•125 + 62.5 experimental dose
•Using a 40mg +20mg low dose- another attempt to work on double-blind
•Arabic caps on next slide
![Page 43: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/43.jpg)
Arabic CAPS
![Page 44: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/44.jpg)
US: MDMA/PTSD Study in
War Veterans•To see if cause of PTSD requires
different method
•Investigate double-blind: 3 dose groups: Low (30 mg + 15mg), medium (75 mg + 37.5) and full dose (125 mg + 62.5)
•Higher risk populations (controlled hypertension and Hepatitis C)
•Potential design for Phase III studies
![Page 45: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/45.jpg)
![Page 46: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/46.jpg)
Timeline •2-3 years to FDA End of Phase II Mtg
•3-5 years for all Phase 3 studies
•1-2 years for FDA review
![Page 47: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/47.jpg)
Zulfi
Text
July 21, 2010
![Page 48: Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder By Rick Doblin, PhD, Executive Director](https://reader035.vdocument.in/reader035/viewer/2022070418/56649e605503460f94b5a386/html5/thumbnails/48.jpg)
Australian MDMA/PTSD
•25k matching grants for Australia MDMA/PTSD
•+ Protocol devel and approval assistance
•+ therapist training
•+ clinical research oversight
•email from someone who contacted rick from Aus- Vets in Aus who wanted to come participate in US study